Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through ...

Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Gallbladder cancer is a rare and often aggressive malignancy that develops in the tissues of the gallbladder — a small, ...

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going ...

Countries like Spain have used 'most-favored-nation' drug pricing for decades. While it may reduce the cost of drugs, it will ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100)The combination demonstrated a favorab ...

Stage 4 RCC is metastatic, with common spread to lungs, bones, liver, brain, and adrenal glands. Understanding IMDC risk is ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, ...